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Introduction: The water-soluble polymer PEI-MP (polyethyleneimine, functionalised with 
methylphosphonate groups) that might be labeled with 188Re (emits high energy β- particles) and 
99mTc presents a strong potential for metabolic radiotherapy and diagnosis, respectively. The aim 
of this study was to evaluate in vivo the potential of 188Re-PEI-MP as therapeutic agent and 
99mTc-PEI-MP as diagnostic agent for bladder carcinoma and osteosarcoma.  
Material and Methods: Cytotoxicity of PEI-MP was investigated in bladder carcinoma cell line 
(CRL-1472) using the MTT test for different concentrations of PEI-MP (1 µM to 1000 µM) and 
incubation times (24h, 48h, 72h and 96h). Radiochemical purity of 99mTc-PEI-MP and 188Re-PEI-
MP was achieved using ascending microchromatography. For the in vivo studies eight groups of 
Balb/c nu/nu mice were used: four normal groups injected with Na99mTcO4 (n=10), 99mTc-PEI-MP 
(n=10), Na188ReO4 (n=18) and 188Re-PEI-MP (n=17), respectively; two with bladder carcinoma 
xenotransplants injected with Na188ReO4 (n=8) and 188Re-PEI-MP (n=12), respectively; two with 
osteosarcoma xenotransplants injected with Na188ReO4 (n=17) and 188Re-PEI-MP (n=19) 
respectively. When the tumors reached the appropriate volume, radiopharmaceuticals were 
 administered by an intravenous injection in the tail vein (22-37MBq), with the animal anesthetized 
and previously placed on the gamma camera detector. Immediately, a dynamic acquisition 
followed, with a 128x128 matrix for 10 min (20 frames, 30 seconds). Static images (2 min) were 
performed with a 256x256 matrix, where each of the six groups was divided into two groups, of 
which one was imaged at 120 minutes, and the other at 240 minutes. For biodistribution 
proposes, mice were euthanized 2 and 4 hours after injection and organ samples were weighted 
and counted in a well-counter to obtain percentage injected activity per gram of organ (%ID/g).  
Results and Discussion: The MTT assay showed that PEI-MP is not cytotoxic. The 
radiochemical purity of 188Re-PEI-MP and 99mTc-PEI-MP was higher than 85%. Biodistribution 
results, with Na188ReO4 and Na99mTcO4, showed a higher uptake by the thyroid, bladder and 
stomach, following a normal biodistribution. The biodistribution with 188Re-PEI-MP and 99mTc-PEI-
MP showed that the excretion of these complexes occurs primarily through the renal system, with 
a small fraction being eliminated by the hepatobiliary system. In mice with osteosarcoma 
tumor/muscle ratio was greater than 1.0, and for mice with bladder carcinoma the tumor/muscle 
ratio was greater than 1.5. 
Conclusions: The 188Re-PEI-MP seems to be promising in the treatment of both types of cancer, 
but with a greater potential for bladder cancer, given its biodistribution and tumor/muscle ratio. 
Following the same biodistribution as 188Re-PEI-MP, 99mTc-PEI-MP seems to be optimal for 
diagnosis and follow up of both types of cancer. 
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